Sunday, November 29, 2015

Johnson & Johnson recalls injectable version of antipsychotic drug Risperdal

Johnson & Johnson's Janssen Pharmaceutical subsidiary said it is recalling one lot of the injectable antipsychotic drug Risperdal Consta.

Johnson & Johnson recalls injectable version of antipsychotic drug Risperdal


Johnson & Johnson's Janssen Pharmaceutical subsidiary said Wednesday that it was recalling one lot of the antipsychotic drug Risperdal Consta.

A link to the recall notice in PDF format is here and gets a brief link on the product web site, which is deep within the Janssen web site.

Janssen's statement says the recall was issued "because the product did not meet our standards."

Reuters reported that a company spokeswoman said the more specific reason was that mold was found in some of the vials that hold the medicine. She said that the company estimates 5,000 dose packs remain in the market. A single lot has about 70,000 dosage packs. A link to the Reuters story is here.

Risperdal Consta is a long-acting, injectable version of Risperdal, which comes in a pill. Both versions are approved for use in bipolar disorder and schizophrenia. The injected version is delivered by healthcare professionals.

The recall does not apply to pill versions of Risperdal. Before losing patent protection, the pill version generated billions of dollars for the company. J&J is also under investigation by the Justice Department, which has been looking into whether the company promoted Risperdal for unapproved uses.

If patients have a reaction, they should contact their doctor.


Inquirer Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Inquirer Staff Writer
Also on
letter icon Newsletter